Expression and effect of related factors of lymphangiogenesis in colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2015.07.018

Abstract

Abstract: The lymphatic metastasis affects prognosis and survival of colorectal cancer seriously, and lymphangiogenesis plays an important role in the lymphatic metastasis. Many factors such as COX2 and MMP7 which are found in many researches recently can promote the expression of VEGFC which can promote the lymphangiogenesis by connecting with its receptor and activating the relevant signal pathway. At present, as these related factors of lymphangiogenesis are found in colorectal cancer, the process of lymphangiogenesis in colorectal cancer becomes more clear, but the exact mechanism of these factors needs to be researched in future.

Key words: Colorectal neoplasms, Endothelial growth factors, Lymphangiogenesis

Zhang Yuemeng, Sun Shanshan, Liu Wenzhi, Gao Wencang. Expression and effect of related factors of lymphangiogenesis in colorectal cancer[J]. Journal of International Oncology, 2015, 42(7): 542-544.

References

［1］ Gao S, Ma JJ, Lu C. Prognostic significance of VEGFC immunohistochemical expression in breast cancer: a metaanalysis［J］. Tumor Biology, 2014, 35(2): 1523-1529. ［2］ Widodo I, Ferronika P, Harijadi A, et al. Clinicopathological significance of lymphangiogenesis and tumor lymphovascular invasion in indonesian breast cancers［J］. Asian Pac J Cancer Prev, 2013, 14(2): 997-1001. ［3］任彦武, 高峰, 宋枫, 等. 结直肠癌组织中VEGFC和Podoplianin表达临床意义分析［J］. 中华肿瘤防治杂志, 2013, 20(20): 1592-1595. ［4］ Wang TB, Chen ZG, Wei XQ, et al. Serum vascular endothelial growth factorC and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer［J］. ANZ J Surg, 2011, 81(10): 694-699. ［5］ Tacconi C, Correale C, Gandelli A, et al. Vascular endothelial growth factor C disrupts the endothellal lymphatic barrier to promote colorectal cancer invasion［J］. Gastroenterology, 2015, In Press. ［6］ Lin PC, Lin YJ, Lee CT, et al. Cyclooxygenase2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients［J］. Oncol Lett, 2013, 6(3): 733-739. ［7］ Liu H, Xiao J, Yang Y, et al. COX2 expression is correlated with VEGFC, lymphangiogenesis and lymph node metastasis in human cervical cancer［J］. Microvasc Res, 2011, 82(2): 131-140. ［8］张涛, 李焱, 高辉, 等. 结肠癌中COX2对VEGFC表达的影响［J］. 现代肿瘤医学, 2009, 17(12): 2401-2403. ［9］ Cao R, Ji H, Feng N, et al. Collaborative interplay beteeen FGF2 and VEGFC promotes lymphangiogenesis and metastasis［J］. Pro Natl Acad Sci USA, 2012, 109(39): 15894-15899. ［10］ Chang LK, GarciaCardena G, Famebo F, et al. Dosedependent response of FGF2 for lymphangiogenesis［J］. Proc Natl Acad Sci USA, 2004, 101(32): 11658-11663. ［11］ Sundlisaeter E, Rosland GV, Hertel JK, et al. Increased lymphatic vascular density is seen before colorectal cancers reach stage Ⅱ and growth factor FGF2 is downregulated in tumor tissue compared with normal mucosa［J］. APMIS, 2009, 117(3): 212-221. ［12］张伟, 于占江, 师岩, 等. 趋化因子受体CCR7的表达与卵巢癌淋巴管入侵及淋巴结转移的关系［J］. 解剖科学进展, 2012, 18(5): 456-459. ［13］武欣, 李坤, 张凡, 等. 大肠癌中CCR7、Lselectin、CD44v6和 MMP9表达及其与淋巴转移的关系［J］. 临床与实验病理学杂志, 2013, 29(1): 32-35. ［14］ Pryczynicz A, Gryko M, Niewiarowska K, et al. Immunohistochemical expression of MMP7 protein and its serum level in colorectal cancer［J］. Folia Histochem Cytobiol, 2013, 51(3): 206-212. ［15］ Kostova E, SlaninkaMiceska M, Labacevski N, et al. Expression of matrix metalloproteinasws 2, 7 and 9 in patuents with colorectal cancer ［J］. Vojnosanit Pregl, 2014, 71(1): 52-59. ［16］李志娟, 蒋卫国, 王劲欧, 等. CD151和MMP7在结直肠癌中的表达及其临床意义［J］. 中国肿瘤临床, 2012, 39(7): 392-395. ［17］吴桂丽, 胡月明, 刘爱东, 等. 结直肠腺癌中MMP7的表达与淋巴管生成的关系［J］. 现代肿瘤医学, 2012, 20(3): 553-557. ［18］ Petrelli F, Coinu A, Ghilardi M, et al. Efficacy of oxaliplatinbased chemotherapy+bevacizumab as firstline treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trialsy［J］. Am J Clin Oncol, 2015, 38(2): 227-233. ［19］ Harada K, Hatanaka K, Kinoshita K, et al. Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as firstline treatment—a case report［J］. Gan To Kagaku Ryoho, 2014, 41(7): 897-900.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[9]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[10]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[11]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[12]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[13]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[14]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[15]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.